PMA device
FoundationOneCDx (F1CDx)
Foundation Medicine, Inc. · Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP, Class III) · First FDA decision Aug 30, 2024, newest Dec 19, 2024Cancer detection and genomic testing
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
0
Naming "FoundationOneCDx"
MAUDE reports
0
Brand "FoundationOneCDx", since 2015
PubMed studies
22
Mentioning "FoundationOneCDx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing FoundationOneCDx (F1CDx)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- FoundationOneCDx (F1CDx)PMA supplement
P170019-S056 · Decided Dec 19, 2024 · 178 days after receipt · Normal 180 Day Track No User Fee
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- FoundationOne®CDx (F1CDx)PMA supplement
P170019-S052 · Decided Aug 30, 2024 · 255 days after receipt · Normal 180 Day Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40210Palmetto GBAUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40278WPS Insurance CorporationUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40226CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40222Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40278WPS Insurance CorporationUpdated Sep 15, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40222Noridian Healthcare Solutions, LLCUpdated Aug 22, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40226CGS Administrators, LLCUpdated Aug 21, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40210Palmetto GBAUpdated Aug 18, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "FoundationOneCDx", any status and sponsor, newest update first.
No registered device study names "FoundationOneCDx".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "FoundationOneCDx", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PQP
14 reports: 11 malfunction, 2 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Hamilton Microlab STAR Liquid Handler; Protocol Configuration Tool (PCT) v2.0.0. Used to conduct F1CDx and F1LCDx.Open, Classified
Z-2951-2026 · Started Jun 10, 2026 · Posted by FDA Aug 14, 2026
Reason given: Software issue that can cause an increase in spontaneous software closures.
Cause as FDA categorized it: Software design · Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
Z-1937-2026 · Started Mar 24, 2026 · Posted by FDA Apr 23, 2026
Reason given: Potential for spontaneous closures of Hamilton HxRunControl software during execution of Autolys protocols after deployment of the PCT software for AutoLys Hamilton STAR.
Cause as FDA categorized it: Software change control · Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
- Sequencing Agent SEQ0067, component of FoundationOne CDx (F1CDx)Open, Classified
Z-1927-2026 · Started Mar 20, 2026 · Posted by FDA Apr 22, 2026
Reason given: Possible increase in phasing, potentially resulting in false-positive BARD1 splice site indel artifact variants
Cause as FDA categorized it: Under Investigation by firm · Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
6 more recall records with a free account
Published research
The most relevant PubMed records for "FoundationOneCDx"[tiab]. The summary above synthesizes these.
- Insights of Clinical Significance From 109ߙ695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.
Heilmann AM, Riess JW, McLaughlin-Drubin M, et al. · Oncologist · 2024Observational Study, Research Support, Non-U.S. Gov't
- Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies.
Janjigian YY, Cecchini M, Shitara K, et al. · JCO Precis Oncol · 2025Research Support, Non-U.S. Gov't
- Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.
Wei B, Kang J, Kibukawa M, et al. · J Mol Diagn · 2022Research Support, Non-U.S. Gov't
- Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types.
Gandara DR, Agarwal N, Gupta S, et al. · J Immunother Cancer · 2025
- Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
Hussain M, Corcoran C, Sibilla C, et al. · Clin Cancer Res · 2022Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Silverman IM, Li M, Murugesan K, et al. · J Mol Diagn · 2022Research Support, Non-U.S. Gov't
- Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
Kasi PM, Lee JK, Pasquina LW, et al. · Clin Cancer Res · 2024
- Uterine Leiomyosarcoma Masquerading as a Malignant Perivascular Epithelioid Cell Tumor: A Diagnostic Challenge.
Natsume T, Yoshida H, Nishikawa T, et al. · Int J Surg Pathol · 2023Case Reports
- [Current Status and Future Direction of Cancer Genomic Medicine in Japan].
Muto M · Gan To Kagaku Ryoho · 2020
- Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study.
Boutros A, Carlino MS, Chaganti R, et al. · JCO Precis Oncol · 2026Research Support, Non-U.S. Gov't
- Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.
Ido M, Fujii K, Mishima H, et al. · BMC Cancer · 2024
- Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting.
Stackland S, Schnabel D, Dinan MA, et al. · J Natl Cancer Inst · 2025
Other devices of this type
Also filed under product code PQP.
- FoundationOne CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOne Liquid CDxFoundation Medicine, Inc. · PMA 2026
- Oncomine Dx Target TestLife Technologies Corporation · PMA 2025
- Guardant360 CDxGuardant Health, Inc. · PMA 2026
- Oncomine Dx Express TestLife Technologies Corporation · PMA 2026
- xT CDxTempus AI, Inc. · PMA 2026
- TruSight Oncology ComprehensiveIllumina, Inc. · PMA 2026
- FoundationOne®Liquid CDxFoundation Medicine, Inc. · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.